Prudential Financial
MLYS icon

Prudential Financial’s Mineralys Therapeutics MLYS Stock Holding History

Prudential Financial’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$252K Sell
9,355
-50,200
-84% -$1.38M ﹤0.01% 2159
2026
Q1 		$1.61M Sell
59,555
-29,510
-33% -$865K ﹤0.01% 1407
2025
Q4 		$3.23M Buy
89,065
+38,640
+77% +$1.55M ﹤0.01% 1085
2025
Q3 		$1.91M Sell
50,425
-301,800
-86% -$6.53M ﹤0.01% 1367
2025
Q2 		$4.77M Buy
352,225
+224,815
+176% +$3.26M 0.01% 926
2025
Q1 		$2.02M Buy
127,410
+1,760
+1% +$20.2K ﹤0.01% 1281
2024
Q4 		$1.55M Buy
125,650
+58,000
+86% +$758K ﹤0.01% 1409
2024
Q3 		$819K Hold
67,650
– – ﹤0.01% 1985
2024
Q2 		$792K Buy
+67,650
New +$852K ﹤0.01% 1963
2023
Q3 		– Sell
-50,770
Closed -$866K – 2663
2023
Q2 		$866K Buy
50,770
+200
+0.4% +$2.99K ﹤0.01% 1874
2023
Q1 		$792K Buy
+50,570
New +$851K ﹤0.01% 1861

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Prudential Financial's MLYS Position: Q2 2026 in Review

Prudential Financial reduced its Mineralys Therapeutics (MLYS) stake by 84% in Q2 2026, selling an estimated $1.38M and leaving 9,355 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #2159.

Prudential Financial first reported a position in MLYS in Q1 2023 and has held it in 11 quarters since. The position peaked at $4.77M in Q2 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Prudential Financial held 9,355 shares of Mineralys Therapeutics worth $252K as of Q2 2026.
  • Prudential Financial sold 50,200 Mineralys Therapeutics shares in Q2 2026, an estimated $1.38M.
  • Mineralys Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2159 holding.
  • Prudential Financial first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 11 quarters since.
  • Prudential Financial's Mineralys Therapeutics position peaked at $4.77M in Q2 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.